施国明

导师简介

施国明，博士，浙江绍兴人，复旦大学附属中山医院肝脏外科主任医师，副教授，硕导。兼任中国抗癌协会结直肠癌肝转移委员会委员、中华医学会肿瘤分会青年委员、绍兴文理学院校友总会副会长、国家自然基金评审专家、Hepatology、Journal of Hepatology、Cancer Res等杂志审稿人，Annals of Transl Med编委等。

学习经历：

1990.09-1994.07 浙江省绍兴卫校 医士专业

1996.09-2002.07 浙江大学best365网页版登录 临床医学 学士（涵）

2002.09-2005.07 昆明best365网页版登录 肝胆外科 硕士

2005.09-2008.07 复旦大学附属中山医院 普通外科学 博士

2015.09-2016.08 哈佛best365网页版登录Brigham & Women’s Hospital 高级访问学者

工作经历：

1994.08-2002.07 best365网页版登录 普外科 医士、医师

2008.08-2012.11 复旦大学附属中山医院 肝外科 主治医师

2012.12-2017.11 复旦大学附属中山医院 肝外科 副主任医师

2014.08-今 复旦大学附属中山医院 肝外科 副教授

2017.12-今 复旦大学附属中山医院 肝外科 主任医师

主要研究方向：肝脏肿瘤基础与临床

主要研究内容：肝癌发生发展与表观、免疫调控

目前承担的主要研究任务：

1．2015年，国家自然基金面上项目“KSR1与Raf结合调控ERK1/2信号诱导肝癌索拉非尼耐药机制研究”立项号：81472840，80万

近期发表的主要论文：

1.Wu D, Hu D, Chen H,Shi G, Fetahu IS, Wu F, Rabidou K, Fang R, Tan L, Xu S, Liu H, Argueta C, Zhang L, Mao F, Yan G, Chen J, Dong Z, Lv R, Xu Y, Wang M, Ye Y, Zhang S, Duquette D, Geng S, Yin C, Lian CG, Murphy GF, Adler GK, Garg R, Lynch L, Yang P, Li Y, Lan F, Fan J, Shi Y, Shi YG.Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer.Nature . 2018 Jul 18. doi: 10.1038/s41586-018-0350-5（IF=41.577，co-first author）.

2.Xie N, Cai JB, Zhang L, Zhang PF, Shen YH, Yang X, Lu JC, Gao DM, Kang Q, Liu LX, Zhang C, Huang XY, Zou H, Zhang XY, Song ZJ, Sun HX, Fu BM, Ke AW,Shi GM.Upregulation of B7-H4 promotes tumor progression of intrahepatic cholangiocarcinoma.Cell Death Dis. 2017 Dec 13;8(12):3205. doi：10.1038/s41419-017-0015-6.(IF5.014，corresponding author)

3.Kang Q, Cai JB, Dong RZ, Liu LX, Zhang C, Zhang PF, Zou H, Xie N, Zhang L, Zhang XY, Song ZJ, Dong ZR, Hu MY, Huang XY, Zhang XW, Ke AW,Shi GM.Mortalin promotes cell proliferation and epithelial mesenchymal transition of intrahepatic cholangiocarcinoma cells in vitro.J Clin Pathol. 2017 Aug;70(8):677-683.(IF2.7，corresponding author)

4.Zhang PF,Li KS,Shen YH,Gao PT,Dong ZR,Cai JB,Zhang C,Huang XY,Tian MX,Hu ZQ,Gao DM,Fan J,Ke AW,Shi GM. Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling.Cell Death Dis.2016 Apr 21;7:e2201. doi: 10.1038/cddis.2015.324. (IF5.014，corresponding author)

5.Bai DS, Wu C, Yang LX, Zhang C, Zhang PF, He YZ, Cai JB, Song ZJ, Dong ZR, Huang XY, Ke AW,Shi GM.UBAP2 negatively regulates the invasion of hepatocellular carcinoma cell by ubiquitinating and degradating Annexin A2.Oncotarget. 2016 Apr 18. doi: 10.18632/oncotarget.8783. (IF6.359，corresponding author)

6. Ke AW, Zhang PF, Shen YH, Gao PT, Dong ZR, Zhang C, Cai JB, Huang XY, Wu C, Zhang L, Kang Q, Liu LX, Xie N, Shen ZZ, Hu MY, Cao Y, Qiu SJ, Sun HC, Zhou J, Fan J,Shi GM. Generation and characterization of a tetraspanin CD151/integrin `6β1-binding domain competitively binding monoclonal antibody for inhibition of tumor progression in HCC. Oncotarget. 2016 Jan;. (IF6.359，corresponding author)

7.Zhang P,Dong Z,Cai J,Zhang C,Shen Z,Ke A,Gao D,Fan J,Shi G. BRD4 promotes tumor growth and epithelial-mesenchymal transition in hepatocellular carcinoma.Int J Immunopathol Pharmacol.2015 Mar;28(1):36-44. (IF1.617，corresponding author)

8. Cai JB,Shi GM, Dong ZR, Ke AW, Ma HH, Gao Q, Shen ZZ, Huang XY, Chen H, Yu DD, Liu LX, Zhang PF, Zhang C, Hu MY, Yang LX, Shi YH, Wang XY, Ding ZB, Qiu SJ, Sun HC, Zhou J, Shi YG, Fan J.Ubiquitin-specific protease 7 accelerates p14(ARF) degradation by deubiquitinating thyroid hormone receptor-interacting protein 12 and promotes hepatocellular carcinoma progression.Hepatology. 2015 May;61(5):1603-14.(共同第一作者，指导，IF11.67)

9.Huang XY, Zhang C, Cai JB,Shi GM, Ke AW, Dong ZR, Zhang PF, Fan J, Peng BG, Zhou J.Comprehensive multiple molecular profile of epithelial mesenchymal transition in intrahepatic cholangiocarcinoma patients.PLoS One. 2014 May 9;9(5):e96860.（共同第一作者，指导，IF3.53）

10.Zhang C, Bai DS, Huang XY,Shi GM, Ke AW, Yang LX, Yang XR, Zhou J, Fan J.Prognostic significance of Capn4 overexpression in intrahepatic cholangiocarcinoma.PLoS One. 2013;8(1):e54619. （共同第一作者，指导，IF4.3）

11. Huang XY, Ke AW,Shi GM, Zhang X, Zhang C, Shi YH, Wang XY, Ding ZB, Xiao YS, Yan J, Qiu SJ, Fan J, Zhou J.αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma.Hepatology. 2013 Jun;57(6):2235-47. (共同第一作者，指导，IF11.67)

12. Huang XY,Shi GM, Devbhandari RP, Ke AW, Wang Y, Wang XY, Wang Z, Shi YH, Xiao YS, Ding ZB, Dai Z, Xu Y, Jia WP, Tang ZY, Fan J, Zhou J.Low level of low-density lipoprotein receptor-related protein 1 predicts an unfavorable prognosis of hepatocellular carcinoma after curative resection.PLoS One. 2012;7(3):e32775. （共同第一作者，指导，IF4.3）

13. Gu FM, Gao Q,Shi GM, Zhang X, Wang J, Jiang JH, Wang XY, Shi YH, Ding ZB, Fan J, Zhou J.Intratumoral IL-17(+) Cells and Neutrophils show Strong Prognostic Significance in Intrahepatic Cholangiocarcinoma.Ann Surg Oncol. 2012 Aug; 19(8):2506-14. （共同第一作者，IF4.2）

14. Devbhandari RP,Shi GM, Ke AW, Wu FZ, Huang XY, Wang XY, Shi YH, Ding ZB, Xu Y, Dai Z, Fan J, Zhou J.Profiling of the tetraspanin CD151 web and conspiracy of CD151/integrin β1 complex in the progression of hepatocellular carcinoma.PLoS One. 2011;6(9):e24901.（共同第一作者，指导，IF4.3）

15. Ke AW,Shi GM, Zhou J, Huang XY, Shi YH, Ding ZB, Wang XY, Devbhandari RP, Fan J.CD151 amplifies signaling by integrin α6β1 to PI3K and induces the epithelial-mesenchymal transition in HCC cells.Gastroenterology. 2011 May;140(5):1629-41.e15.(共同第一作者，IF12.9)

16.Shi GM, Ke AW, Zhou J, Wang XY, Xu Y, Ding ZB, Devbhandari RP, Huang XY, Qiu SJ, Shi YH, Dai Z, Yang XR, Yang GH, Fan J.CD151 modulates expression of matrix metalloproteinase 9 and promotes neoangiogenesis and progression of hepatocellular carcinoma.Hepatology. 2010 Mar 15;52(1):183-196. (IF10.8)

17. Huang XY, Ke AW,Shi GM, Ding ZB, Devbhandari RP, Gu FM, Li QL, Dai Z, Zhou J, Fan J.Overexpression of CD151 as an adverse marker for intrahepatic cholangiocarcinoma patients.Cancer. 2010 Dec 1;116(23):5440-51.(共同第一作者，指导，IF5.2)

18.Ke AW,Shi GM, Zhou J, Wu FZ, Ding ZB, Hu MY, Xu Y, Song ZJ, Wang ZJ, Wu JC, Bai DS, Li JC, Liu KD, Fan J.Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma.Hepatology. 2009;49(2):491-503.（共同第一作者，IF11.3）

19.Shi GM, Xu Y, Fan J, Zhou J, Yang XR, Qiu SJ, Liao Y, Wu WZ, Ji Y, Ke AW, Ding ZB, He YZ, Wu B, Yang GH, Qin WZ, Zhang W, Zhu J, Min ZH, Wu ZQ.Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. JCRCO. 2008;134(11):1155-63.(IF2.6)

20.Ding ZB, Shi YH, Zhou J,Shi GM, Ke AW, Qiu SJ, Wang XY, Dai Z, Xu Y, Fan J. Liver-Intestine Cadherin Predicts Microvascular Invasion and Poor Prognosis of Hepatitis B Virus-Positive Hepatocellular Carcinoma. Cancer. 2009;115(20):4753-65(共同第一作者，IF5.2)

专利

1 一种鼠源单克隆抗体CD151 9B及其应用（专利号：201410204122.2），国家发明专利权 中华人民共和国国家知识产权局 2014.10.20

主要科研获奖

1.明治生命科学奖杰出奖（2013）

2.肿瘤微环境调控肝癌转移复发的机制研究，教育部自然科学奖一等奖，第5完成人（2015）

联系方式：

E-mail:shigm@usx.edu.cn